172 related articles for article (PubMed ID: 24440211)
1. Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain).
Arrieta F; Rubio-Terrés C; Rubio-Rodríguez D; Magaña A; Piñera M; Iglesias P; Nogales P; Calañas A; Novella B; Botella-Carretero JI; Debán C; Zamarrón I; Mora G; Balsa JA; Vázquez C;
Endocrinol Nutr; 2014 Apr; 61(4):193-201. PubMed ID: 24440211
[TBL] [Abstract][Full Text] [Related]
2. [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study].
Liebl A; Spannheimer A; Reitberger U; Görtz A
Med Klin (Munich); 2002 Dec; 97(12):713-9. PubMed ID: 12491064
[TBL] [Abstract][Full Text] [Related]
3. How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China?
Wang W; Fu CW; Pan CY; Chen W; Zhan S; Luan R; Tan A; Liu Z; Xu B
Value Health; 2009 Sep; 12(6):923-9. PubMed ID: 19824187
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
Martin S; Schramm W; Schneider B; Neeser K; Weber C; Lodwig V; Heinemann L; Scherbaum WA; Kolb H
Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):495-501. PubMed ID: 17853332
[TBL] [Abstract][Full Text] [Related]
5. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
O'Brien JA; Patrick AR; Caro J
Clin Ther; 2003 Mar; 25(3):1017-38. PubMed ID: 12852716
[TBL] [Abstract][Full Text] [Related]
6. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
[TBL] [Abstract][Full Text] [Related]
7. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).
Willis M; Asseburg C; He J
J Med Econ; 2013 Aug; 16(8):1007-21. PubMed ID: 23718682
[TBL] [Abstract][Full Text] [Related]
8. The cost of treating type 2 diabetes (CODEIRE).
Nolan JJ; O'Halloran D; McKenna TJ; Firth R; Redmond S
Ir Med J; 2006; 99(10):307-10. PubMed ID: 17274175
[TBL] [Abstract][Full Text] [Related]
9. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
[TBL] [Abstract][Full Text] [Related]
10. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
Wolfenstetter SB
Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
[TBL] [Abstract][Full Text] [Related]
11. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.
Pelletier EM; Shim B; Ben-Joseph R; Caro JJ
Pharmacoeconomics; 2009; 27(6):479-90. PubMed ID: 19640011
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs of people with type 2 diabetes mellitus in the Basque Country (Spain).
Nuño-Solinís R; Alonso-Morán E; Arteagoitia Axpe JM; Ezkurra Loiola P; Orueta JF; Gaztambide S
Endocrinol Nutr; 2016 Dec; 63(10):543-550. PubMed ID: 27825534
[TBL] [Abstract][Full Text] [Related]
13. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain.
Mata-Cases M; Casajuana M; Franch-Nadal J; Casellas A; Castell C; Vinagre I; Mauricio D; Bolíbar B
Eur J Health Econ; 2016 Nov; 17(8):1001-1010. PubMed ID: 26542160
[TBL] [Abstract][Full Text] [Related]
14. [Costs of temporary disability in Spain related to diabetes mellitus and its complications].
Vicente-Herrero MT; Terradillos García MJ; Capdevila García LM; Ramírez Iñiguez de la Torre MV; López-González AA
Endocrinol Nutr; 2013 Oct; 60(8):447-55. PubMed ID: 23726468
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes mellitus in China: a preventable economic burden.
Wang W; McGreevey WP; Fu C; Zhan S; Luan R; Chen W; Xu B
Am J Manag Care; 2009 Sep; 15(9):593-601. PubMed ID: 19747024
[TBL] [Abstract][Full Text] [Related]
16. Economic cost associated with type II diabetes in Spanish patients.
Ballesta M; Carral F; Olveira G; Girón JA; Aguilar M
Eur J Health Econ; 2006 Dec; 7(4):270-5. PubMed ID: 16850331
[TBL] [Abstract][Full Text] [Related]
17. Costs of treatment and complications of adult type 1 diabetes.
Franciosi M; Lucisano G; Amoretti R; Capani F; Bruttomesso D; Di Bartolo P; Girelli A; Leonetti F; Morviducci L; Vitacolonna E; Nicolucci A
Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):606-11. PubMed ID: 22749531
[TBL] [Abstract][Full Text] [Related]
18. [Costs of known diabetes mellitus in Spain].
Hart WM; Espinosa C; Rovira J
Med Clin (Barc); 1997 Sep; 109(8):289-93. PubMed ID: 9379750
[TBL] [Abstract][Full Text] [Related]
19. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain.
Larrañaga I; Arteagoitia JM; Rodriguez JL; Gonzalez F; Esnaola S; Piniés JA;
Diabet Med; 2005 Aug; 22(8):1047-53. PubMed ID: 16026371
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
